Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study.
about
Targeting Schlemm's Canal in the Medical Therapy of Glaucoma: Current and Future Considerations.Topical treatment of glaucoma: established and emerging pharmacology.Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm's canal endothelial cells.Efficacy of Ripasudil as a Second-line Medication in Addition to a Prostaglandin Analog in Patients with Exfoliation Glaucoma: A Pilot Study.Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma.Additive Intraocular Pressure-Lowering Effects of Ripasudil with Glaucoma Therapeutic Agents in Rabbits and MonkeysComparative Study of the Effects of Trabecular Meshwork Outflow Drugs on the Permeability and Nitric Oxide Production in Trabecular Meshwork Cells.Effect of Cromakalim Prodrug 1 (CKLP1) on Aqueous Humor Dynamics and Feasibility of Combination Therapy With Existing Ocular Hypotensive Agents.Changes in Glaucoma Medication during the Past Eight Years and Future Directions in Japan Based on an Insurance Medical Claim Database.Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma.Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy.Effects of ripasudil hydrochloride hydrate (K-115), a Rho-kinase inhibitor, on ocular blood flow and ciliary artery smooth muscle contraction in rabbits.Quantitative analysis of ripasudil hydrochloride hydrate and its impurities by reversed-phase high-performance liquid chromatography after precolumn derivatization: Identification of four impurities.Effects of Ripasudil Hydrochloride Hydrate Instillation on Pupil Dynamics.Intraocular pressure elevation precedes a phagocytosis decline in a model of pigmentary glaucoma.GCDB: a glaucomatous chemogenomics database for in silico drug discovery
P2860
Q33665753-DC3B2E9C-8EA4-4E03-BCDD-14E3F8FEC0B4Q36365495-A6F552B9-2CF4-454E-A457-BFD3C741A756Q36499750-4A0D2CB7-7A02-4D2A-8549-3EB723188ED3Q38872011-1390237E-7993-4EC9-B121-D04A3FB26860Q39207696-F2C16991-35E5-4787-9B35-3A09D7479B75Q42127523-47BB94FC-0F56-4A2E-A878-3A70E23B4368Q42262056-C2050F06-1A16-4BEF-BF0C-541D3324245CQ43991565-5AE029C3-5675-41C2-9B8E-49B109ACA0FAQ47187983-02D0BDF0-A573-473C-BE79-F26E76C12F84Q47822162-6C336F2D-DFD7-4606-B834-3A5831CE3C2FQ48151026-056E6F3F-26F1-413A-A8D7-47D1CE0C70C3Q50921528-0915BFF0-09BD-488B-8F5F-EA028DCCDD84Q51259572-8D225EBB-72C6-4B9A-BE30-CBC0107BB1B7Q51726357-D043BC07-1884-4D53-A0C1-FBE1FFB99B98Q55039131-0C6C49CD-2DF7-4A22-AB63-561812E1D00DQ58132502-231316F2-925C-420E-9926-DAFDDEBB48BF
P2860
Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Intra-ocular pressure-lowering ...... , open-label, crossover study.
@ast
Intra-ocular pressure-lowering ...... , open-label, crossover study.
@en
Intra-ocular pressure-lowering ...... , open-label, crossover study.
@nl
type
label
Intra-ocular pressure-lowering ...... , open-label, crossover study.
@ast
Intra-ocular pressure-lowering ...... , open-label, crossover study.
@en
Intra-ocular pressure-lowering ...... , open-label, crossover study.
@nl
prefLabel
Intra-ocular pressure-lowering ...... , open-label, crossover study.
@ast
Intra-ocular pressure-lowering ...... , open-label, crossover study.
@en
Intra-ocular pressure-lowering ...... , open-label, crossover study.
@nl
P2093
P2860
P356
P1433
P1476
Intra-ocular pressure-lowering ...... , open-label, crossover study.
@en
P2093
Haruki Abe
Hideki Suganami
Hidenobu Tanihara
K-115 Clinical Study Group
Makoto Araie
Tetsuya Yamamoto
Toshihiro Inoue
Yasuaki Kuwayama
P2860
P304
P356
10.1111/AOS.12599
P577
2014-12-09T00:00:00Z